DDInter1376 DDInter1806
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter . A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects .
Tildrakizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Tildrakizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Tildrakizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Human adenovirus e serotype 4 strain cl-68578 antigen
Tildrakizumab {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Tildrakizumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Tildrakizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Tildrakizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Tildrakizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live